Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 165-166, Issue -, Pages 77-95Publisher
ELSEVIER
DOI: 10.1016/j.addr.2020.02.006
Keywords
Cerebrospinal fluid; Subarachnoid space; Nanotechnology; Polymer; Gene delivery; Intracisternal; Intraventricular; Lumbar; Intracerebroventricular; Central nervous system
Categories
Funding
- National Institutes of Health [R01NS111292, R01HD099543, R21NS107985, R56AG057581]
- Morgan Adams Foundation
- Ian's Friends Foundation
Ask authors/readers for more resources
Administration of substances directly into the cerebrospinal fluid (CSF) that surrounds the brain and spinal cord is one approach that can circumvent the blood-brain barrier to enable drug delivery to the central nervous system (CNS). However, molecules that have been administered by intrathecal injection, which includes intraventricular, intracisternal, or lumbar locations, encounter new barriers within the subarachnoid space. These barriers include relatively high rates of turnover as CSF clears and potentially inadequate delivery to tissue or cellular targets. Nanomedicine could offer a solution. In contrast to the fate of freely administered drugs, nanomedicine systems can navigate the subarachnoid space to sustain delivery of therapeutic molecules, genes, and imaging agents within the CNS. Some evidence suggests that certain nanomedicine agents can reach the parenchyma following intrathecal administration. Here, we will address the preclinical and clinical use of intrathecal nanomedicine, including nanoparticles, microparticles, dendrimers, micelles, liposomes, polyplexes, and other colloidalal materials that function to alter the distribution of molecules in tissue. Our review forms a foundational understanding of drug delivery to the CSF that can be built upon to better engineer nanomedicine for intrathecal treatment of disease. (C) 2020 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available